This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): BVdU, bromovinyl deoxyuridine, brivudine
Description: RP101 is an inhibitor of heat-shock protein 27 (HSP27) which is believed to play a role in gene amplification leading to multidrug resistance.
RESprotect and Avantogen
In September 2004, Avantogen signed an agreement with the German company RESprotect GmbH to acquire the North American licence to RP101.
SciClone and Resistys (Avantogen)
In April 2007, SciClone Pharmaceuticals acquired the exclusive rights in the United States and Canada to develop and commercialize RP101. SciClone acquired the rights from Resistys, a wholly owned subsidiary of Avantogen Oncology.
SciClone and RESprotect
In June 2011, SciClone returned the exclusive rights to develop and commercialize RP101 in the United States and Canada to RESprotect GmbH.
RESprotect and RedHill
In August 2014, RedHill Biopharma and RESprotect GmbH entered into a binding exclusive option agreement for the acquisition of the oncology drug candidate RP101 and next generation compounds.
Under the terms of the agreement, RedHill has the option to acquire the worldwide exclusive rights to RP101 for all...See full deal structure in Biomedtracker
Partners: Avantogen Oncology RedHill Biopharma Ltd.
Additional information available to subscribers only: